<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="178209">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00775190</url>
  </required_header>
  <id_info>
    <org_study_id>2008-184</org_study_id>
    <nct_id>NCT00775190</nct_id>
  </id_info>
  <brief_title>Side Effect Profiles of Brand Name Versus Generic Oral Contraceptives</brief_title>
  <official_title>Side Effect Profiles of Brand Name Versus Generic Oral Contraceptives</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>William Beaumont Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>William Beaumont Hospitals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized control trial of Ortho tricyclen versus Trinessa (generic equivalent)
      to determine if they have similar effects. Women will be randomized to receive either Ortho
      tricyclen or Trinessa oral contraceptives and will be asked to keep a daily dairy of any
      symptoms or bleeding experienced. Once a month, participants will be asked to complete a
      survey.

      The objective is to compare generic oral contraceptives (OCPs) and brand name OCPs with
      respect to side effect profiles including bleeding patterns, mood changes, nausea and
      vomiting, frequency of menstrual cramps, breast tenderness, elevation in blood pressure,
      stroke, blood clots and patient compliance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blind randomized controlled trial of Ortho tricyclen™ vs. Trinessa™
      (generic equivalent) to determine if they have similar effects on bleeding patterns, namely
      days of menstrual flow, amount of bleeding, and intermenstrual bleeding. Women will score
      these parameters using a survey with objective measures for days of bleeding, amount of
      flow, and days of breakthrough bleeding. As secondary outcomes, we will compare the side
      effect profiles of each in regards to nausea, vomiting, breast tenderness, menstrual cramps,
      mood changes, and thromboembolic events.

      Patients will record in their daily diary if one of the outcomes occurs or not. We will
      observe whether the events occur and the number of occurrences within the six month time
      period.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    unale to recruit , progress report not filed by PI
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding patterns -Break through bleeding -Amount of bleeding -Days of bleeding</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>nausea and vomiting, breast tenderness, mood changes, elevation in blood pressure, stroke, blood clots, compliance and failure of contraception.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Ortho tricyclen™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Trinessa™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ortho tricyclen</intervention_name>
    <description>brand name oral contraceptive</description>
    <arm_group_label>Ortho tricyclen™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trinessa</intervention_name>
    <description>generic oral contraceptive</description>
    <arm_group_label>Trinessa™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  nonsmoker

          -  not pregnant

          -  not planning to become pregnant in the next 6 months

          -  not taking hormonal birth control for at least 3 months previous to entering the
             study

          -  no history of fibroids

          -  no history of ovarian cysts

          -  no history of dysfunctional uterine bleeding

        Exclusion Criteria:

          -  pregnant

          -  under the age of 18

          -  over the age of 35

          -  history of irregular uterine bleeding

          -  history of ovarian cysts

          -  history of fibroids

          -  history of migraines with aura

          -  history of liver disease

          -  family or personal history of thromboembolism

          -  mental disabilities

          -  desire to become pregnant in the next six months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frances Bechek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>William Beaumont Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>October 17, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>William Beaumont Hospitals</investigator_affiliation>
    <investigator_full_name>Frances Bechek, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>birth control pills</keyword>
  <keyword>oral contraceptives</keyword>
  <keyword>brand name</keyword>
  <keyword>generic</keyword>
  <keyword>side effects</keyword>
  <keyword>oral contraceptive side effects</keyword>
  <keyword>dysfunctional uterine bleeding</keyword>
  <keyword>pre-menstrual symptoms</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
